A Family of Laminin α2 Chain-Deficient Mouse Mutants: Advancing the Research on LAMA2-CMD

Overview

Journal Front Mol Neurosci

Specialty Molecular Biology

Date 2020 May 28

PMID 32457577

Citations 14

Authors

Kinga I Gawlik

Madeleine Durbeej

Affiliations

Soon will be listed here.

Abstract

The research on laminin α2 chain-deficient congenital muscular dystrophy (LAMA2-CMD) advanced rapidly in the last few decades, largely due to availability of good mouse models for the disease and a strong interest in preclinical studies from scientists all over the world. These mouse models continue to provide a solid platform for understanding the LAMA2-CMD pathology. In addition, they enable researchers to test laborious, necessary routines, but also the most creative scientific approaches in order to design therapy for this devastating disorder. In this review we present animals belonging to the laminin α2 chain-deficient "" mouse family (, / , / , / , et al.) and a summary of the scientific progress they facilitated. We also raise a few questions that need to be addressed in order to maximize the usefulness of laminin α2 murine mutants and to further advance the LAMA2-CMD studies. We believe that research opportunities offered by the mouse models for LAMA2-CMD will continuously support our efforts to find a treatment for the disease.

Citing Articles

Comprehensive analysis of LMNB2 in pan-cancer and identification of its biological role in sarcoma.

Guo Y, Zhang M, Luo Y, Li Y, Xu Y, Wang N Aging (Albany NY). 2025; 17(1):203-216.

PMID: 39774004 PMC: 11810055. DOI: 10.18632/aging.205962.

Laminin-α2 chain deficiency in skeletal muscle causes dysregulation of multiple cellular mechanisms.

Martins S, Ribeiro V, Melo C, Paulino-Cavaco C, Antonini D, Naidu S Life Sci Alliance. 2024; 7(12).

PMID: 39379105 PMC: 11463332. DOI: 10.26508/lsa.202402829.

Thrombospondin-4 deletion does not exacerbate muscular dystrophy in β-sarcoglycan-deficient and laminin α2 chain-deficient mice.

Zaren P, Gawlik K Sci Rep. 2024; 14(1):14757.

PMID: 38926599 PMC: 11208443. DOI: 10.1038/s41598-024-65473-8.

Pharmacotherapeutic Approaches to Treatment of Muscular Dystrophies.

Rawls A, Diviak B, Smith C, Severson G, Acosta S, Wilson-Rawls J Biomolecules. 2023; 13(10).

PMID: 37892218 PMC: 10605463. DOI: 10.3390/biom13101536.

Nerve pathology is prevented by linker proteins in mouse models for -related muscular dystrophy.

Reinhard J, Porrello E, Lin S, Pelczar P, Previtali S, Ruegg M PNAS Nexus. 2023; 2(4):pgad083.

PMID: 37038437 PMC: 10082391. DOI: 10.1093/pnasnexus/pgad083.

References

Moll J, Barzaghi P, Lin S, Bezakova G, Lochmuller H, Engvall E . An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature. 2001; 413(6853):302-7. DOI: 10.1038/35095054. View

Rooney J, Knapp J, Hodges B, Wuebbles R, Burkin D . Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy. Am J Pathol. 2012; 180(4):1593-602. PMC: 3349899. DOI: 10.1016/j.ajpath.2011.12.019. View

Vilquin J, Guerette B, Puymirat J, Yaffe D, Tome F, Fardeau M . Myoblast transplantations lead to the expression of the laminin alpha 2 chain in normal and dystrophic (dy/dy) mouse muscles. Gene Ther. 1999; 6(5):792-800. DOI: 10.1038/sj.gt.3300889. View

Oliveira B, Gawlik K, Durbeej M, Holmberg J . Exploratory Profiling of Urine MicroRNAs in the Mouse Model of LAMA2-CMD: Relation to Disease Progression. PLoS Curr. 2018; 10. PMC: 6140833. DOI: 10.1371/currents.md.d0c203c018bc024f2f4c9791ecb05f88. View

Chun S, Rasband M, Sidman R, Habib A, Vartanian T . Integrin-linked kinase is required for laminin-2-induced oligodendrocyte cell spreading and CNS myelination. J Cell Biol. 2003; 163(2):397-408. PMC: 2173507. DOI: 10.1083/jcb.200304154. View

Vohra R, Accorsi A, Kumar A, Walter G, Girgenrath M . Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A). PLoS One. 2015; 10(9):e0138254. PMC: 4575026. DOI: 10.1371/journal.pone.0138254. View

Ferletta M, Kikkawa Y, Yu H, Talts J, Durbeej M, Sonnenberg A . Opposing roles of integrin alpha6Abeta1 and dystroglycan in laminin-mediated extracellular signal-regulated kinase activation. Mol Biol Cell. 2003; 14(5):2088-103. PMC: 165099. DOI: 10.1091/mbc.e03-01-0852. View

Hager M, Bigotti M, Meszaros R, Carmignac V, Holmberg J, Allamand V . Cib2 binds integrin alpha7Bbeta1D and is reduced in laminin alpha2 chain-deficient muscular dystrophy. J Biol Chem. 2008; 283(36):24760-9. PMC: 3259829. DOI: 10.1074/jbc.M801166200. View

Harandi V, Oliveira B, Allamand V, Friberg A, Fontes-Oliveira C, Durbeej M . Antioxidants Reduce Muscular Dystrophy in the Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy. Antioxidants (Basel). 2020; 9(3). PMC: 7139799. DOI: 10.3390/antiox9030244. View

10.

Talts J, Sasaki T, Miosge N, Gohring W, Mann K, Mayne R . Structural and functional analysis of the recombinant G domain of the laminin alpha4 chain and its proteolytic processing in tissues. J Biol Chem. 2000; 275(45):35192-9. DOI: 10.1074/jbc.M003261200. View

11.

Gawlik K, Korner Z, Oliveira B, Durbeej M . Early skeletal muscle pathology and disease progress in the dy/dy mouse model of congenital muscular dystrophy with laminin α2 chain-deficiency. Sci Rep. 2019; 9(1):14324. PMC: 6778073. DOI: 10.1038/s41598-019-50550-0. View

12.

Fukada S, Yamamoto Y, Segawa M, Sakamoto K, Nakajima M, Sato M . CD90-positive cells, an additional cell population, produce laminin alpha2 upon transplantation to dy(3k)/dy(3k) mice. Exp Cell Res. 2007; 314(1):193-203. DOI: 10.1016/j.yexcr.2007.09.020. View

13.

Wood A, Cohen N, Joshi V, Li M, Costin A, Hersey L . RGD inhibition of itgb1 ameliorates laminin-α2-deficient zebrafish fibre pathology. Hum Mol Genet. 2018; 28(9):1403-1413. DOI: 10.1093/hmg/ddy426. View

14.

van Lunteren E, Moyer M, Leahy P . Gene expression profiling of diaphragm muscle in alpha2-laminin (merosin)-deficient dy/dy dystrophic mice. Physiol Genomics. 2005; 25(1):85-95. DOI: 10.1152/physiolgenomics.00226.2005. View

15.

Oliveira J, Gruber A, Cardoso M, Taipa R, Fineza I, Goncalves A . LAMA2 gene mutation update: Toward a more comprehensive picture of the laminin-α2 variome and its related phenotypes. Hum Mutat. 2018; 39(10):1314-1337. DOI: 10.1002/humu.23599. View

16.

Pillers D, Kempton J, Duncan N, Pang J, Dwinnell S, Trune D . Hearing loss in the laminin-deficient dy mouse model of congenital muscular dystrophy. Mol Genet Metab. 2002; 76(3):217-24. DOI: 10.1016/s1096-7192(02)00039-2. View

17.

Talts J, Andac Z, Gohring W, Brancaccio A, Timpl R . Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. EMBO J. 1999; 18(4):863-70. PMC: 1171179. DOI: 10.1093/emboj/18.4.863. View

18.

Gawlik K . At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy-Are We Closer to Effective Treatment for Patients?. Int J Mol Sci. 2018; 19(5). PMC: 5983724. DOI: 10.3390/ijms19051490. View

19.

Rabie M, Yanay N, Fellig Y, Konikov-Rozenman J, Nevo Y . Improvement of motor conduction velocity in hereditary neuropathy of LAMA2-CMD dy/dy mouse model by glatiramer acetate. Clin Neurophysiol. 2019; 130(10):1988-1994. DOI: 10.1016/j.clinph.2019.07.029. View

20.

Cohn R, Mayer U, Saher G, Herrmann R, van der Flier A, Sonnenberg A . Secondary reduction of alpha7B integrin in laminin alpha2 deficient congenital muscular dystrophy supports an additional transmembrane link in skeletal muscle. J Neurol Sci. 1999; 163(2):140-52. DOI: 10.1016/s0022-510x(99)00012-x. View